Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials

Rafael Caparica, Marco Bruzzone, Georges El Hachem, Marcello Ceppi, Matteo Lambertini, João Glasberg, Evandro de Azambuja, Jean Luc Van Laethem, Alain Hendlisz

Research output: Contribution to journalReview article

Abstract

Background: The role of adjuvant chemotherapy in biliary tract cancer is controversial. We performed a systematic review and meta-analysis to assess the effect of adjuvant chemotherapy in biliary tract cancer patients. Methods: A literature search was performed to identify randomized controlled trials (RCTs) comparing adjuvant chemotherapy versus observation, and a pooled analysis was conducted using the random-effect model. Results: Three RCTs (N = 866) were included. No difference was observed between chemotherapy and observation in terms of OS (HR 0.91; 95 %CI, 0.75–1.09; p = 0.295), whereas a significant improvement in RFS was shown (HR 0.83; 95 %CI, 0.69-0.99; p = 0.040). No subgroup that benefited most from adjuvant chemotherapy was identified, although a trend was observed in N+ patients (HR 0.83; 95 %CI, 0.65–1.08; p = 0.165). Discussion: Adjuvant chemotherapy yields a significant RFS benefit in biliary tract cancer patients and should be considered for those who are able to tolerate additional treatment after surgery.

Original languageEnglish
Article number102940
JournalCritical Reviews in Oncology/Hematology
Volume149
DOIs
Publication statusPublished - May 2020

Keywords

  • Adjuvant therapy
  • Biliary tract cancer
  • Chemotherapy
  • Relapse
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials'. Together they form a unique fingerprint.

  • Cite this